Physician profile
Casey Browning
NPI 1689009441
$738.97
in general payments reported to CMS, 2019-2025
15 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $43.90 · 2023: $73.22 · 2024: $123 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $695.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $179.47 | 2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $104.13 | 2024-2025 | Farxiga, Wainua, Lokelma |
| Abbott Laboratories | $67.64 | 2022-2025 | Mitraclip |
| Novartis Pharmaceuticals Corporation | $64.16 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $48.26 | 2023-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $44.93 | 2023-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.26 | 2025 | Lifevest |
| Bridgebio Pharma, INC. | $38.95 | 2025 | Attruby |
| Medtronic, INC. | $30.14 | 2025 | Linq II |
| Boston Scientific Corporation | $28.41 | 2023 | Watchman Access System |
| Amgen INC. | $25.97 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $19.74 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $15.97 | 2023 | Inpefa |
| Pfizer INC. | $15.08 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Browning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.